This is the authors' abstract. We don't add key points for this paper.
Introduction: Many studies over the past decade have shown that the Ki-67 index is a valuable biomarker for the diagnosis, classification of gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).In the present work, therefore, we have decided to evaluate the expression of Ki-67 based on the intensity of the stain, basing our hypothesis on the fact that the Ki-67 protein is continuously degraded during G0 and G1 and the production constantly increases from the start of the S phase until mitotic exit and therefore the longer a cell has spent hibernating, the lower its Ki-67 level will be when it re-enters the cell cycle. Objective : The aim of this study was to evaluate whether a new immunohistochemical scoring method would be more effective in classifying NETs by reducing staining heterogeneity. Methods : 87 patients with GEP-NET were retrospectively analyzed. Along with the traditional Ki-67 rating, a new score based on the intensity of staining (semiquant Ki-67) was developed. The classification difference between the two methods was determined. Results : The classification of the classification changed significantly when the Ki-67 semi-quant index was used. The percentage of G1 patients increased from 18.4% to 60.9%, while the G2 patients decreased from 66.7% to 29.9% and the G3 patients also decreased from 14.9% to 9.2% %. Conclusions : The new analysis allowed to re-quantify the positive percentages of Ki-67, which can be used both as a marker of proliferation but also as a tool to map tumor dynamics that can influence the diagnosis and guide the choice of therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Faviana et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: